

Special Issue

Advances in the Development of Prophylactic and Therapeutic Cancer Vaccines

Message from the Guest Editors

Our knowledge and understanding of the tumor microenvironment and tumor immunity, dictated by the direct roles of tumor cells and immune cells, have expanded significantly over the last few decades. Consequently, oncology and immunotherapy have witnessed unprecedented progress in the race to develop effective therapeutic compounds, being linked to fewer immune-related adverse events compared to their previous counterparts. We have seen tremendous successes in treating cancers, from therapeutic monoclonal antibodies targeting tumor-associated or tumor-specific antigens to immune checkpoint inhibitors and antibody–drug conjugates. Yet, due to resistance development or poor response, a large number of cancer patients cannot benefit from such therapies.

This Special Issue focuses on the role of new developments and technologies in developing prophylactic and therapeutic cancer vaccines based on B-cell or T-cell peptides, nucleic acids, cancer cells, or viral vectors, as well as their formulation, to achieve strong cancer immunity.

Guest Editors

Dr. Joshua Tobias

Institute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, 1090 Vienna, Austria

Prof. Dr. Ursula Wiedermann

Center for Pathophysiology, Infectiology and Immunology, Institute of Specific Prophylaxis and Tropical Medicine, Medical University of Vienna, 1090 Vienna, Austria

Deadline for manuscript submissions

30 June 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/253789

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).